BRIEF-Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Biohaven Ltd. +9.69% Pre
Biohaven Ltd. BHVN | 10.98 10.88 | +9.69% -0.91% Pre |
March 19 (Reuters) - Biohaven Ltd BHVN.N:
BIOHAVEN'S PHASE 2 OBESITY STUDY WITH TALDEFGROBEP ALFA, A NOVEL MYOSTATIN-ACTIVIN PATHWAY INHIBITOR, COMPLETES ENROLLMENT
Source text: ID:nPn9VHmYna
Further company coverage: BHVN.N
